The Paradigm Shift in the Korean Hospital MSO Market

Surpassing 100 Billion Won in Annual Revenue? The Paradigm Shift in the Korean Hospital MSO Market

[2025-2026 MSO Revenue & Operating Profit Research] The Reality of the Shifting Domestic Hospital MSO Market

Back in 2023, our column titled "Performance Analysis of Domestic Franchise Hospital MSOs" garnered intense interest from private practices and hospital management. Now, just 2 to 3 years later, the domestic hospital MSO (Management Service Organization) market is undergoing a massive paradigm shift beyond imagination.

Are franchise-type hospital MSOs still raking in enormous amounts of money today? After tracking the recently updated financial data of major companies, we found that the market has already reorganized into a 'battlefield of mega-capital,' where the line between winners and losers is starkly divided.

[Core Briefing] What Has Changed in the 2025-2026 MSO Market?

• The Birth of '100 Billion Won' Mega MSOs: The previous revenue ceiling that hovered around 30 billion won has been shattered. Through the combination of multiple medical departments (multi-brands) and aggressive expansion, an MSO has emerged that exploded its revenue nearly tenfold in just two years, conquering the 100 billion won milestone.

  
  

• Shocking Polarization (A Phenomenal 45% Surplus vs. A Dismal Shift to Deficit): It is not just about external growth. While one MSO solidified its internal stability with an overwhelming operating profit margin of 45.7%, the 1st-generation large-scale non-invasive aesthetics (petit) and dermatology MSOs that once dominated the market have delivered a shock by consecutively turning to minus (-) deficits. Why did their fates diverge so drastically?

  
  

• The Bare Face of Capital, A Rampage Toward IPOs: Unlike older MSOs that used to lower their operating profits due to tax issues in the past, emerging giant MSOs are expanding their revenue and operating profit scales at a terrifying speed. This is clearly a move by mega-capital taking dead aim at 'IPOs' and 'Exits.'

  
  

[JAY's Management Insight]

The positive function of MSOs, which drove the growth of aesthetic and plastic surgery private practices and became the foundation of the K-Beauty industry, is undeniable.

However, we must be wary of outdated management relying on a single brand, as well as the 'influx of deformed capital' that targets indemnity insurance or infringes upon clinical rights. The era has come where only true corporate-type MSOs—where clinical practice, capital, and hospital management are in perfect harmony—can survive.

So, which brand actually hit 100 billion won in revenue? And which 1st-generation MSOs have fallen into the swamp of deficits?

If you are curious about the newly reorganized 2026 domestic MSO performance ranking table, as well as the exact real names and financial data of the brands that transitioned to a surplus or deficit, check out the full column via the links below.

🔗 [2026 Hospital MSO Revenue Comparison Update] (Link)

🔗 [2023 Hospital MSO Revenue Comparison] (Link)